Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat Added to Ivacaftor for Treatment of Cystic Fibrosis
23 févr. 2017 16h05 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a pharmaceutical company historically focused on developing innovative solutions for people with...
Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2016 Financial Results
13 févr. 2017 16h05 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a pharmaceutical company historically focused on developing innovative solutions for people with...
Nivalis Therapeutics Announces Corporate Restructuring
12 janv. 2017 16h10 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Jan. 12, 2017 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic...
Nivalis Therapeutics Announces Review of Strategic Alternatives
03 janv. 2017 18h00 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic...
Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat for Treatment of Cystic Fibrosis
28 nov. 2016 16h05 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today...
Nivalis Therapeutics Announces Completion of Enrollment in Second Phase 2 Study of Cavosonstat for Treatment of Cystic Fibrosis
14 nov. 2016 16h05 HE
|
Nivalis Therapeutics, Inc.
- Study is Evaluating Cavosonstat in Patients Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated with Kalydeco™ - Data Expected in the First Quarter of 2017 BOULDER, Colo., Nov. ...
Nivalis Therapeutics Reports Third Quarter 2016 Financial Results
07 nov. 2016 16h05 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical-stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today...
Nivalis Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
03 nov. 2016 16h05 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic...
Nivalis Therapeutics to Present at Two Upcoming Investor Conferences
02 nov. 2016 16h05 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today...
Nivalis Therapeutics to Present at Two Upcoming Investor Conferences
06 sept. 2016 07h30 HE
|
Nivalis Therapeutics, Inc.
BOULDER, Colo., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today...